In 2023, the systemic hormonal preparations (excluding sex hormones and insulins) sales in Japan were $20 US Dollars per capita. For 2024, an anticipated value of $21 suggests a gradual uptrend. From 2024 to 2028, a steady growth is expected with annual increases of approximately 0.3, reaching $22.3 by 2028. This indicates a consistent year-on-year growth percentage in the range of 1.4% to 1.6%. The compound annual growth rate (CAGR) over the forecasted five years is about 1.5%, reflecting moderate and sustained expansion in this segment.
Future trends to monitor include potential impacts from regulatory changes on hormone therapies, advancements in biotechnology that could introduce new hormonal products, and demographic shifts, particularly in Japan's aging population, enhancing demand for specific hormonal treatments. These factors might significantly influence market dynamics and growth trajectories.
